Zusammenfassung
Diese Einschätzung wurde am 17.12.18 mit einem Endkurs von 6,36 € beendet. Herbe Verluste von -76,42 % verzeichnete die BUY Einschätzung von melinda. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Endologix | - | - | - | - |
| iShares Core DAX® | -3,03 % | 0,65 % | 12,27 % | 18,19 % |
| iShares Nasdaq 100 | -3,55 % | -3,01 % | 27,68 % | 47,28 % |
| iShares Nikkei 225® | -3,94 % | 1,94 % | 10,52 % | 10,49 % |
| iShares S&P 500 | -1,52 % | -0,60 % | 25,86 % | 45,57 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Endologix diskutieren
SecteurEquipement, fournitures et distribution médicale Agenda 02/10 Investor Meeting
Develops and manufactures medical devices for the treatment of aortic disorders
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA).
Its products include AFX Endovascular AAA System, Nellix and Ovation.
The company was founded in March 1992 and is headquartered in Irvine, CA.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA).
Its products include AFX Endovascular AAA System, Nellix and Ovation.
The company was founded in March 1992 and is headquartered in Irvine, CA.
Nombre d'employés : 675 personnes.
(Vom Mitglied beendet)